Dr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination

Now Viewing

EP: 1.Dr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination

EP: 2.Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients

EP: 3.COVID-19 Vaccination Strategies Should Consider Infection Risks for CAR T-Cell Therapy Recipients

EP: 4.Efforts Needed to Evaluate How CAR T-Cell Therapy Recipients Respond to COVID-19 Vaccination

Muhammad Bilal Abid, MD, MRCP, assistant professor of medicine, Divisions of Hematology/Oncology and Infectious Diseases, Medical College of Wisconsin, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

Patients who undergo CAR T-cell therapy should be revaccinated for COVID-19 following infusion, because the treatment may cause them to lose their response to the vaccine, according to Abid.

Additionally, it has been shown that if the patient received the COVID-19 vaccine within 6 months of receiving CAR T-cell infusion, response rates were not as favorable, Abid explains. Patients who received the vaccination more than 6 months after infusion have improved response rates, likely because they have better immune reconstitution, Abid concludes.